- Home
- FINV vs AGIO Comparison
FINV vs AGIO Comparison
Compare FINV & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINV
- AGIO
- Stock Information
- Founded
- FINV 2007
- AGIO 2007
- Country
- FINV China
- AGIO United States
- Employees
- FINV N/A
- AGIO N/A
- Industry
- FINV Finance: Consumer Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- FINV Finance
- AGIO Health Care
- Exchange
- FINV Nasdaq
- AGIO Nasdaq
- Market Cap
- FINV 2.0B
- AGIO 2.3B
- IPO Year
- FINV N/A
- AGIO 2013
- Fundamental
- Price
- FINV $7.92
- AGIO $36.01
- Analyst Decision
- FINV Strong Buy
- AGIO Buy
- Analyst Count
- FINV 2
- AGIO 6
- Target Price
- FINV $11.55
- AGIO $57.00
- AVG Volume (30 Days)
- FINV 2.3M
- AGIO 692.1K
- Earning Date
- FINV 08-20-2025
- AGIO 10-30-2025
- Dividend Yield
- FINV 3.57%
- AGIO N/A
- EPS Growth
- FINV 32.63
- AGIO N/A
- EPS
- FINV 1.49
- AGIO 11.13
- Revenue
- FINV $1,927,901,951.00
- AGIO $40,875,000.00
- Revenue This Year
- FINV $13.45
- AGIO $28.19
- Revenue Next Year
- FINV $9.59
- AGIO $152.14
- P/E Ratio
- FINV $5.23
- AGIO $3.23
- Revenue Growth
- FINV 7.84
- AGIO 30.57
- 52 Week Low
- FINV $5.14
- AGIO $23.42
- 52 Week High
- FINV $11.08
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- FINV 36.14
- AGIO 44.75
- Support Level
- FINV $7.74
- AGIO $32.70
- Resistance Level
- FINV $9.73
- AGIO $41.10
- Average True Range (ATR)
- FINV 0.39
- AGIO 1.79
- MACD
- FINV -0.10
- AGIO -0.12
- Stochastic Oscillator
- FINV 9.05
- AGIO 39.40
About FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.